中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 3
Mar.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(3): 699-706

Role of stem cell-derived exosomes in treatment of liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.03.034
  • 1.

    Guizhou Provincial Key Laboratory of Cell Engineering, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, China

  • 2.

    Division of Liver Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

  • 3.

    Collaborative Innovation Center of Tissue Damage Repair and Regenerative Medicine, Ministry of Education, Zunyi Medical University, Zunyi, Guizhou 563001, China

  • 4.

    Zunyi Stem Cell and Regenerative Medicine Engineering Research Center, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, China

Research funding:

Capital Clinical Characteristic Application Research on Funded Projects (Z151100004015019);

National Foundation for Science and Technology Development (2017ZX10203201-004)

More Information
  • Corresponding author: YU Limei, ylm720@sina.com (ORCID: 0000-0002-3377-1202); YOU Shaoli, youshaoli1972@163.com (ORCID: 0000-0001-8689-8509)
  • Received Date: 2022-07-30
  • Accepted Date: 2022-09-21
  • Published Date: 2023-03-20
    Abstract
  • The liver is easily affected by a variety of factors to induce liver damage, which can cause disorders in the synthesis, detoxification, metabolism, and biotransformation functions of the liver in severe cases, and at present, there is still a lack of efficient clinical treatment methods for end-stage liver diseases such as liver failure and decompensated liver cirrhosis. Recent studies have confirmed the clinical efficacy of stem cells, and treatment methods based on stem cell-derived exosomes have become a research hotspot. This article introduces the advantages of treatment based on stem cell-derived exosomes, the research advances in related mechanisms, and the current status of preclinical research. Current research findings suggest that treatment based on stem cell-derived exosomes has a good application prospect in the treatment of liver diseases, but it is still needed to conduct in-depth preclinical and clinical studies.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    BARTUNEK J, BEHFAR A, DOLATABADI D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics[J]. J Am Coll Cardiol, 2013, 61(23): 2329-2338. DOI: 10.1016/j.jacc.2013.02.071.
    [2]
    SILVA JD, LOPES-PACHECO M, PAZ A, et al. Mesenchymal stem cells from bone marrow, adipose tissue, and lung tissue differentially mitigate lung and distal organ damage in experimental acute respiratory distress syndrome[J]. Crit Care Med, 2018, 46(2): e132-e140. DOI: 10.1097/CCM.0000000000002833.
    [3]
    SUK KT, YOON JH, KIM MY, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial[J]. Hepatology, 2016, 64(6): 2185-2197. DOI: 10.1002/hep.28693.
    [4]
    JAIBAJI M, JAIBAJI R, VOLPIN A. Mesenchymal stem cells in the treatment of cartilage defects of the knee: A systematic review of the clinical outcomes[J]. Am J Sports Med, 2021, 49(13): 3716-3727. DOI: 10.1177/0363546520986812.
    [5]
    CHRIST B, BRVCKNER S, WINKLER S. The Therapeutic promise of mesenchymal stem cells for liver restoration[J]. Trends Mol Med, 2015, 21(11): 673-686. DOI: 10.1016/j.molmed.2015.09.004.
    [6]
    KALLURI R, LEBLEU VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977. DOI: 10.1126/science.aau6977.
    [7]
    PAN BT, JOHNSTONE RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor[J]. Cell, 1983, 33(3): 967-978. DOI: 10.1016/0092-8674(83)90040-5.
    [8]
    PEGTEL DM, GOULD SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88: 487-514. DOI: 10.1146/annurev-biochem-013118-111902.
    [9]
    RANI S, RYAN AE, GRIFFIN MD, et al. Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic applications[J]. Mol Ther, 2015, 23(5): 812-823. DOI: 10.1038/mt.2015.44.
    [10]
    THÉRY C, WITWER KW, AIKAWA E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7(1): 1535750. DOI: 10.1080/20013078.2018.1535750.
    [11]
    MELDOLESI J. Exosomes and ectosomes in intercellular communication[J]. Curr Biol, 2018, 28(8): R435-R444. DOI: 10.1016/j.cub.2018.01.059.
    [12]
    TSUCHIYA A, KOJIMA Y, IKARASHI S, et al. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases[J]. Inflamm Regen, 2017, 37: 16. DOI: 10.1186/s41232-017-0045-6.
    [13]
    BORRELLI DA, YANKSON K, SHUKLA N, et al. Extracellular vesicle therapeutics for liver disease[J]. J Control Release, 2018, 273: 86-98. DOI: 10.1016/j.jconrel.2018.01.022.
    [14]
    RONG X, LIU J, YAO X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J]. Stem Cell Res Ther, 2019, 10(1): 98. DOI: 10.1186/s13287-019-1204-2.
    [15]
    WATANABE T, TSUCHIYA A, TAKEUCHI S, et al. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles[J]. Regen Ther, 2020, 14: 252-261. DOI: 10.1016/j.reth.2020.03.012.
    [16]
    TAKEUCHI S, TSUCHIYA A, IWASAWA T, et al. Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis[J]. NPJ Regen Med, 2021, 6(1): 19. DOI: 10.1038/s41536-021-00132-4.
    [17]
    ZITO G, MICELI V, CARCIONE C, et al. Human amnion-derived mesenchymal stromal/stem cells pre-conditioning inhibits inflammation and apoptosis of immune and parenchymal cells in an in vitro model of liver ischemia/reperfusion[J]. Cells, 2022, 11(4): 709. DOI: 10.3390/cells11040709.
    [18]
    LIU Y, LOU G, LI A, et al. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages[J]. EBioMedicine, 2018, 36: 140-150. DOI: 10.1016/j.ebiom.2018.08.054.
    [19]
    SHAO M, XU Q, WU Z, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p[J]. Stem Cell Res Ther, 2020, 11(1): 37. DOI: 10.1186/s13287-020-1550-0.
    [20]
    FAN Y, HERR F, VERNOCHET A, et al. Human fetal liver mesenchymal stem cell-derived exosomes impair natural killer cell function[J]. Stem Cells Dev, 2019, 28(1): 44-55. DOI: 10.1089/scd.2018.0015.
    [21]
    GUO L, LAI P, WANG Y, et al. Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response[J]. Int Immunopharmacol, 2020, 84: 106541. DOI: 10.1016/j.intimp.2020.106541.
    [22]
    LEE SC, JEONG HJ, LEE SK, et al. Hypoxic conditioned medium from human adipose-derived stem cells promotes mouse liver regeneration through JAK/STAT3 signaling[J]. Stem Cells Transl Med, 2016, 5(6): 816-825. DOI: 10.5966/sctm.2015-0191.
    [23]
    TAN CY, LAI RC, WONG W, et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models[J]. Stem Cell Res Ther, 2014, 5(3): 76. DOI: 10.1186/scrt465.
    [24]
    YAN Y, JIANG W, TAN Y, et al. hucMSC exosome-derived GPX1 is required for the recovery of hepatic oxidant injury[J]. Mol Ther, 2017, 25(2): 465-479. DOI: 10.1016/j.ymthe.2016.11.019.
    [25]
    TEMNOV A, ROGOV K, ZHALIMOV V, et al. The effect of a mesenchymal stem cell conditioned medium fraction on morphological characteristics of hepatocytes in acetaminophen-induced acute liver failure: a preliminary study[J]. Hepat Med, 2019, 11: 89-96. DOI: 10.2147/HMER.S196354.
    [26]
    HONG HE, KIM OH, KWAK BJ, et al. Antioxidant action of hypoxic conditioned media from adipose-derived stem cells in the hepatic injury of expressing higher reactive oxygen species[J]. Ann Surg Treat Res, 2019, 97(4): 159-167. DOI: 10.4174/astr.2019.97.4.159.
    [27]
    SUN C, SHI C, DUAN X, et al. Exosomal microRNA-618 derived from mesenchymal stem cells attenuate the progression of hepatic fibrosis by targeting Smad4[J]. Bioengineered, 2022, 13(3): 5915-5927. DOI: 10.1080/21655979.2021.2023799.
    [28]
    ÁLVAREZ-VIEJO M. Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective[J]. World J Stem Cells, 2020, 12(2): 100-109. DOI: 10.4252/wjsc.v12.i2.100.
    [29]
    LOU G, CHEN Z, ZHENG M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases[J]. Exp Mol Med, 2017, 49(6): e346. DOI: 10.1038/emm.2017.63.
    [30]
    PIRES AO, MENDES-PINHEIRO B, TEIXEIRA FG, et al. Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: a proteomic analysis[J]. Stem Cells Dev, 2016, 25(14): 1073-1083. DOI: 10.1089/scd.2016.0048.
    [31]
    WANG ZG, HE ZY, LIANG S, et al. Comprehensive proteomic analysis of exosomes derived from human bone marrow, adipose tissue, and umbilical cord mesenchymal stem cells[J]. Stem Cell Res Ther, 2020, 11(1): 511. DOI: 10.1186/s13287-020-02032-8.
    [32]
    ZHAO S, LIU Y, PU Z. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro[J]. Drug Des Devel Ther, 2019, 13: 2887-2897. DOI: 10.2147/DDDT.S220190.
    [33]
    HAGA H, YAN IK, TAKAHASHI K, et al. Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice[J]. Stem Cells Transl Med, 2017, 6(4): 1262-1272. DOI: 10.1002/sctm.16-0226.
    [34]
    RONG X, LIU J, YAO X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J]. Stem Cell Res Ther, 2019, 10(1): 98. DOI: 10.1186/s13287-019-1204-2.
    [35]
    LU FB, CHEN DZ, CHEN L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying MicroRNA-223-3p[J]. Mol Cells, 2019, 42(12): 906-918. DOI: 10.14348/molcells.2019.2283.
    [36]
    LIU Y, LOU G, LI A, et al. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages[J]. EBioMedicine, 2018, 36: 140-150. DOI: 10.1016/j.ebiom.2018.08.054.
    [37]
    JIN Y, WANG J, LI H, et al. Extracellular vesicles secreted by human adipose-derived stem cells (hASCs) improve survival rate of rats with acute liver failure by releasing lncRNA H19[J]. EBioMedicine, 2018, 34: 231-242. DOI: 10.1016/j.ebiom.2018.07.015.
    [38]
    WU HY, ZHANG XC, JIA BB, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acetaminophen-induced acute liver failure through activating ERK and IGF-1R/PI3K/AKT signaling pathway[J]. J Pharmacol Sci, 2021, 147(1): 143-155. DOI: 10.1016/j.jphs.2021.06.008.
    [39]
    CHEN L, XIANG B, WANG X, et al. Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure[J]. Stem Cell Res Ther, 2017, 8(1): 9. DOI: 10.1186/s13287-016-0453-6.
    [40]
    ZHANG S, JIANG L, HU H, et al. Pretreatment of exosomes derived from hUCMSCs with TNF-α ameliorates acute liver failure by inhibiting the activation of NLRP3 in macrophage[J]. Life Sci, 2020, 246: 117401. DOI: 10.1016/j.lfs.2020.117401.
    [41]
    CHEN L, ZHANG J, YANG L, et al. The effects of conditioned medium derived from mesenchymal stem cells cocultured with hepatocytes on damaged hepatocytes and acute liver failure in rats[J]. Stem Cells Int, 2018, 2018: 9156560. DOI: 10.1155/2018/9156560.
    [42]
    JIAO Y, LU W, XU P, et al. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure[J]. Hepatol Int, 2021, 15(4): 957-969. DOI: 10.1007/s12072-021-10217-3.
    [43]
    MA L, WEI J, ZENG Y, et al. Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J]. Drug Deliv, 2022, 29(1): 440-453. DOI: 10.1080/10717544.2022.2030428.
    [44]
    BANG OY, KIM EH. Mesenchymal stem cell-derived extracellular vesicle therapy for stroke: challenges and progress[J]. Front Neurol, 2019, 10: 211. DOI: 10.3389/fneur.2019.00211.
    [45]
    EGGENHOFER E, BENSELER V, KROEMER A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion[J]. Front Immunol, 2012, 3: 297. DOI: 10.3389/fimmu.2012.00297.
    [46]
    VOLAREVIC V, MARKOVIC BS, GAZDIC M, et al. Ethical and safety issues of stem cell-based therapy[J]. Int J Med Sci, 2018, 15(1): 36-45. DOI: 10.7150/ijms.21666.
    [47]
    LÖRINCZ ÁM, TIMÁR CI, MAROSVÁRI KA, et al. Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes[J]. J Extracell Vesicles, 2014, 3: 25465. DOI: 10.3402/jev.v3.25465.
    [48]
    SHOKRAVI S, BORISOV V, ZAMAN BA, et al. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review[J]. Stem Cell Res Ther, 2022, 13(1): 192. DOI: 10.1186/s13287-022-02825-z.
    [49]
    CHENG Y, ZENG Q, HAN Q, et al. Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes[J]. Protein Cell, 2019, 10(4): 295-299. DOI: 10.1007/s13238-018-0529-4.
    [50]
    WIKLANDER OP, NORDIN JZ, O'LOUGHLIN A, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting[J]. J Extracell Vesicles, 2015, 4: 26316. DOI: 10.3402/jev.v4.26316.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (650) PDF downloads(107) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return